aap achieves Double-Digit Sales Growth in H1 2010
(Thomson Reuters ONE) -
aap Implantate AG / aap achieves Double-Digit Sales Growth in H1 2010 processed and transmitted by Hugin AS. The issuer is solely responsible for the content of this announcement.
aap Implantate AG, a medical technology company listed in the Frankfurt Stock
Exchange's Prime Standard segment, achieved double-digit first-half year sales
growth to EUR 12.8 million at product level, according to preliminary figures.
Product sales are up by 11% on the previous year's first-half total of EUR 11.5
million, adjusted by previous year project sales, sales by the Analytics
division, which was sold in December 2009, and other one-time effects amounting
to EUR 3.2 million. Sales revenue for the second quarters of each year show a
25% increase on product level from EUR 5.6 million (adjusted by one-time effects
of EUR 0.7 million) to EUR 7.0 million.
With new product launches, introduction of existing products in new markets and
additional project sales on the basis of the targets defined in the Management
Agenda 2010, the pace of this sales trend is to be accelerated further. The
focus is the WSG System product launch, the expansion of the cannulated screws
business in the U.S. market and marketing of the Jason(®) G collagen fleece
impregnated with antibiotics. After a final review and assurance of intellectual
property protection, we are currently considering various options for the WSG
System market launch. The Company could for instance sell it under aap label or,
as a recent option, license it as an OEM product to one of the leading global
orthopaedic companies.
Interest in aap's R&D partner program has remained strong. We are involved in
talks at an advanced stage with several partners and continue to anticipate the
completion of two license agreements for 2010 of which at least one is to be
concluded in the third quarter of 2010.
aap's operational success is based on structured and efficient internal
processes in IT and organization. Legal restructuring aims to simplify our
organizational structure, for which as a next step we plan to merge the German
cement and biomaterials production sites in Dieburg by June 2011. In the IT
sector, international networking and standardization will be further optimized
and the existing ERP system extended systematically.
So as not to lose sight of our critical mass target, aap monitors the market and
regularly analyzes interesting companies. To optimize the return from our
attractive R&D pipeline and to boost our sales strength and marketing
competence, we are evaluating mainly companies that would offer substantial
sales synergies.
aap plans to publish the Q2 2010 report in full on August 11, 2010.
_____
aap is a medical technology company that develops, manufactures and markets
biomaterials and implants for the areas Ortho/Trauma/Spine. Its product
portfolio includes bone cements, bone graft substitutes, antibiotic carriers,
and implants for fracture healing and joint replacement. In addition to its
Berlin HQ the Company has sites in Dieburg and Obernburg near Frankfurt am Main
and Nijmegen in the Netherlands. aap Implantate AG stock has been listed in the
Prime Standard segment of the Frankfurt Stock Exchange since May 16, 2003.
For inquiries please contact:
aap Implantate AG, Nanette Huedepohl, Head of Corporate Communications,
Lorenzweg 5, 12099 Berlin, Germany, Tel.: +49 30 7501 9133, fax: +49
30 7501 9290, n.huedepohl(at)aap.de
For more details please visit www.aap.de and www.aap-bioimplants.com
[HUG#1430068]
--- End of Message ---
aap Implantate AG
Lorenzweg 5 Berlin Germany
ISIN: DE0005066609;
Listed: Freiverkehr in Börse Stuttgart,
Freiverkehr in Hanseatische Wertpapierbörse zu Hamburg,
Freiverkehr in Börse Berlin,
Freiverkehr in Börse Düsseldorf,
Freiverkehr in Bayerische Börse München,
Freiverkehr in Niedersächsische Börse zu Hannover,
Prime Standard in Frankfurter Wertpapierbörse,
Regulierter Markt in Frankfurter Wertpapierbörse;
This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients.
The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of the information contained therein.
All reproduction for further distribution is prohibited.
Source: aap Implantate AG via Thomson Reuters ONE
Unternehmensinformation / Kurzprofil:
Datum: 07.07.2010 - 12:22 Uhr
Sprache: Deutsch
News-ID 23603
Anzahl Zeichen: 0
contact information:
Town:
Berlin
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 262 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"aap achieves Double-Digit Sales Growth in H1 2010"
steht unter der journalistisch-redaktionellen Verantwortung von
aap Implantate AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
